Jul. 31 at 7:44 PM
$NTLA
Regarding reimbursement from insurers; with a sustained attack-free rate of 62%, it is very beneficial to treat as many patients as possible with Lonvo-z.
Suppose an insurer has 100 HAE patients under its care. On average, these patients cost
$640,000 per year (plus an annual inflation adjustment of about 3%).
The Lonvo-z treatment will likely cost
$2,000,000.
Assuming an average treatment age of 30 years, a saving of about 50 years of HAE medication multiplied by
$640,000 per year (+inflation adjustment) is
$32,000,000 over one lifetime multiplied by the 62 (of the 100) patients who are completely attack-free (and hopefully remain so in the long term). This represents a saving of approximately
$2,000,000,000 in costs on these 62 human lives over their entire lifetimes.
Of course, the
$2,000,000 for the remaining 38 patients for whom the Lonvo-z treatment is ineffective and who must be put back on IV HAE medication must still be deducted =
$76,000,000 in wasted costs.
